http://seekingalpha.com/article/1759302-important-catalysts-appro...

http://seekingalpha.com/article/1759302-important-catalysts-approaching-for-these-biotechs?source=yahoo


Sunshine Heart has a catalyst for its medical device in one week:

Partial data for its C-Pulse device is expected to be released at the 2013 Transcatheter Cardiovascular Therapeutics meeting on 10/28/13.

The C-Pulse device is designed to treat clinical symptoms associated with Class III and ambulatory Class IV heart failure. If proven successful, patients who suffer from heart failure would be able to engage in normal activities that "healthy people" partake in.

The C-Pulse System utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries.

While early in the developmental phase, we believe C-Pulse has the potential to revolutionize the treatment of Class III and ambulatory Class IV heart failure.

When Heartware International (HTWR) received CE-Mark approval in January 2009, it had a market cap of $200MM. Sunshine's current market cap is $132.88M, so we strongly feel Sunshine is very speculation undervalued, especially when compared to other vascular assist device companies at this stage in their product development cycles, such as Heartware.